Ken Griffin: Encompass Health EHC Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 310 M | Venta |
2,554,703
-8,401
| -0.3% | -USD 990 k | 0.03% | 394 |
|
|
2026
Q2 | USD 259 M | Compra |
2,563,104
+2,051,217
| +401% | +USD 212 M | 0.03% | 435 |
|
|
2026
Q1 | USD 49.5 M | Compra |
511,887
+394,416
| +336% | +USD 40.4 M | 0.01% | 1369 |
|
|
2025
Q4 | USD 12.5 M | Venta |
117,471
-194,183
| -62% | -USD 22.5 M | ﹤0.01% | 2960 |
|
|
2025
Q3 | USD 39.6 M | Venta |
311,654
-668,742
| -68% | -USD 79.6 M | 0.01% | 1615 |
|
|
2025
Q2 | USD 120 M | Compra |
980,396
+40,341
| +4% | +USD 4.61 M | 0.02% | 650 |
|
|
2025
Q1 | USD 95.2 M | Compra |
940,055
+506,139
| +117% | +USD 49.4 M | 0.02% | 728 |
|
|
2024
Q4 | USD 40.1 M | Venta |
433,916
-341,339
| -44% | -USD 33.5 M | 0.01% | 1474 |
|
|
2024
Q3 | USD 74.9 M | Venta |
775,255
-761,162
| -50% | -USD 68.4 M | 0.01% | 912 |
|
|
2024
Q2 | USD 132 M | Compra |
1,536,417
+672,404
| +78% | +USD 56.4 M | 0.03% | 534 |
|
|
2024
Q1 | USD 71.4 M | Compra |
864,013
+286,230
| +50% | +USD 21 M | 0.01% | 951 |
|
|
2023
Q4 | USD 38.5 M | Venta |
577,783
-1,292,946
| -69% | -USD 83.7 M | 0.01% | 1388 |
|
|
2023
Q3 | USD 126 M | Compra |
1,870,729
+862,748
| +86% | +USD 59.3 M | 0.03% | 511 |
|
|
2023
Q2 | USD 68.3 M | Venta |
1,007,981
-114,111
| -10% | -USD 7.15 M | 0.01% | 825 |
|
|
2023
Q1 | USD 60.7 M | Venta |
1,122,092
-361,328
| -24% | -USD 21 M | 0.01% | 927 |
|
|
2022
Q4 | USD 88.7 M | Compra |
1,483,420
+468,326
| +46% | +USD 25.5 M | 0.02% | 712 |
|
|
2022
Q3 | USD 45.9 M | Compra |
1,015,094
+1,010,217
| +20,714% | +USD 50.5 M | 0.01% | 1140 |
|
|
2022
Q2 | USD 274 k | Venta |
4,877
-68,820
| -93% | -USD 4.44 M | ﹤0.01% | 9994 |
|
|
2022
Q1 | USD 5.24 M | Venta |
73,697
-82,029
| -53% | -USD 5.38 M | ﹤0.01% | 4081 |
|
|
2021
Q4 | USD 10.2 M | Venta |
155,726
-89,080
| -36% | -USD 5.78 M | ﹤0.01% | 3050 |
|
|
2021
Q3 | USD 18.4 M | Venta |
244,806
-940,668
| -79% | -USD 74.4 M | ﹤0.01% | 2127 |
|
|
2021
Q2 | USD 92.5 M | Compra |
1,185,474
+82,103
| +7% | +USD 6.88 M | 0.02% | 717 |
|
|
2021
Q1 | USD 90.4 M | Compra |
1,103,371
+691,878
| +168% | +USD 56.7 M | 0.02% | 636 |
|
|
2020
Q4 | USD 34 M | Venta |
411,493
-442,440
| -52% | -USD 32.7 M | 0.01% | 1278 |
|
|
2020
Q3 | USD 55.5 M | Compra |
853,933
+660,151
| +341% | +USD 42.6 M | 0.02% | 790 |
|
|
2020
Q2 | USD 12 M | Venta |
193,782
-999,959
| -84% | -USD 67.8 M | ﹤0.01% | 2019 |
|
|
2020
Q1 | USD 76.4 M | Compra |
1,193,741
+565,697
| +90% | +USD 41 M | 0.03% | 448 |
|
|
2019
Q4 | USD 43.5 M | Venta |
628,044
-169,331
| -21% | -USD 11.6 M | 0.02% | 859 |
|
|
2019
Q3 | USD 50.5 M | Compra |
797,375
+62,655
| +9% | +USD 3.96 M | 0.02% | 757 |
|
|
2019
Q2 | USD 46.6 M | Compra |
734,720
+282,806
| +63% | +USD 17.3 M | 0.02% | 767 |
|
|
2019
Q1 | USD 26.4 M | Venta |
451,914
-31,501
| -7% | -USD 2.01 M | 0.01% | 1108 |
|
|
2018
Q4 | USD 29.8 M | Compra |
483,415
+403,317
| +504% | +USD 28.8 M | 0.02% | 928 |
|
|
2018
Q3 | USD 6.24 M | Compra |
80,098
+73,486
| +1,111% | +USD 5.62 M | ﹤0.01% | 2703 |
|
|
2018
Q2 | USD 448 k | Venta |
6,612
-704
| -10% | -USD 44.2 k | ﹤0.01% | 6551 |
|
|
2018
Q1 | USD 418 k | Venta |
7,316
-166,922
| -96% | -USD 8.99 M | ﹤0.01% | 6206 |
|
|
2017
Q4 | USD 8.61 M | Venta |
174,238
-72,180
| -29% | -USD 3.45 M | 0.01% | 1880 |
|
|
2017
Q3 | USD 11.4 M | Compra |
246,418
+86,370
| +54% | +USD 3.87 M | 0.01% | 1489 |
|
|
2017
Q2 | USD 7.75 M | Compra |
160,048
+70,174
| +78% | +USD 3.23 M | 0.01% | 1677 |
|
|
2017
Q1 | USD 3.85 M | Compra |
89,874
+53,138
| +145% | +USD 2.19 M | ﹤0.01% | 2310 |
|
|
2016
Q4 | USD 1.52 M | Compra |
36,736
+21,888
| +147% | +USD 893 k | ﹤0.01% | 3294 |
|
|
2016
Q3 | USD 602 k | Compra |
14,848
+6,053
| +69% | +USD 247 k | ﹤0.01% | 4568 |
|
|
2016
Q2 | USD 341 k | Compra |
8,795
+666
| +8% | +USD 26.2 k | ﹤0.01% | 5185 |
|
|
2016
Q1 | USD 306 k | Venta |
8,129
-19,003
| -70% | -USD 660 k | ﹤0.01% | 5235 |
|
|
2015
Q4 | USD 945 k | Compra |
27,132
+26,093
| +2,511% | +USD 933 k | ﹤0.01% | 3769 |
|
|
2015
Q3 | USD 40 k | Venta |
1,039
-55,624
| -98% | -USD 2.43 M | ﹤0.01% | 7923 |
|
|
2015
Q2 | USD 2.61 M | Compra |
56,663
+52,540
| +1,274% | +USD 2.35 M | ﹤0.01% | 2818 |
|
|
2015
Q1 | USD 183 k | Venta |
4,123
-73,394
| -95% | -USD 3.16 M | ﹤0.01% | 6434 |
|
|
2014
Q4 | USD 2.98 M | Venta |
77,517
-357,598
| -82% | -USD 14 M | ﹤0.01% | 2547 |
|
|
2014
Q3 | USD 16.1 M | Compra |
+435,115
| Nuevas | +USD 16.7 M | 0.02% | 1053 |
|
|
2014
Q2 | – | Venta |
-47,460
| Cerradas | -USD 1.7 M | – | 8204 |
|
|
2014
Q1 | USD 1.7 M | Venta |
47,460
-882
| -2% | -USD 28.9 k | ﹤0.01% | 2902 |
|
|
2013
Q4 | USD 1.61 M | Compra |
+48,342
| Nuevas | +USD 1.69 M | ﹤0.01% | 2757 |
|
|
2013
Q3 | – | Venta |
-2,956
| Cerradas | -USD 85 k | – | 6762 |
|
|
2013
Q2 | USD 85 k | Sin cambios |
2,956
| – | – | ﹤0.01% | 5333 |
|
Otros fondos que tienen EHC en su portafolio
Posición de Ken Griffin en EHC: resumen de T3 2026
Ken Griffin redujo su participación en Encompass Health (EHC) en 0.33% durante T3 2026, al vender acciones por un valor estimado de USD 990 k y quedarse con 2,554,703 acciones valuadas en USD 310 M. La posición representa 0.03% del portafolio y ocupa el puesto #394.
Ken Griffin reportó por primera vez una posición en EHC en T2 2013 y desde entonces la ha mantenido en 52 trimestres. Al cierre de T3 2026, 630 fondos que sigue Wall St. Rank mantienen una posición en EHC.
- Al cierre de T3 2026, Ken Griffin tenía 2,554,703 acciones de Encompass Health con un valor de USD 310 M.
- Ken Griffin vendió 8,401 acciones de Encompass Health en T3 2026, por un valor estimado de USD 990 k.
- Encompass Health representó el 0.03% del portafolio de Ken Griffin en T3 2026 y fue su posición número 394.
- Ken Griffin reportó por primera vez una posición en Encompass Health en T2 2013 y desde entonces la ha mantenido en 52 trimestres.
- Al cierre de T3 2026, 630 fondos que sigue Wall St. Rank tenían Encompass Health en su portafolio.
Según el informe 13F de Citadel Advisors correspondiente a T3 2026, presentado el 16 nov 2026.